Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges Publisher Pubmed



Khorasani ABS1 ; Sanaei MJ2 ; Pourbagherisigaroodi A2 ; Ghaffari SH3 ; Bashash D2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  2. 2. Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: International Immunopharmacology Published:2021


Abstract

The application of the CAR T cell therapy in hematologic malignancies holds prosperous results that intensified the unprecedented enthusiasm to employ this fascinating strategy in other types of human malignancies. Although the researchers invested a great deal of effort to exploit the utmost efficacy of these cells in the context of solid tumors, few articles reviewed obstacles and opportunities. The current review aims to provide comprehensive literature of recent advances of CAR T cell therapy in a wide range of solid tumors; and also, to discuss the original data obtained from international research laboratories on this topic. Despite promising results, several radical obstacles are on the way of this approach. This review discusses the most important drawbacks and also responds to questions on how the intrinsic features of solid tumors in addition to the tumor microenvironment-related challenges and the immune-relating adverse effects can curb satisfactory outcomes of CAR T cells. The last section allocates a special focus on innovative and contemporary policies which have already been adopted to surmount these challenges. Finally, we comment on the future research aspects in which the efficacy, as well as the safety of CAR T cell therapy, might be improved. © 2021 Elsevier B.V.
Other Related Docs
11. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
19. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
22. Tumor Immunology, Clinical Immunology (2022)
28. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
34. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
39. Advances in Pharmacotherapy for Neuroblastoma, Expert Opinion on Pharmacotherapy (2021)
41. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
44. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
49. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
50. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)